Schedule 13G ownership disclosure
Adamis Pharmaceuticals Corp
Security class unavailable · CUSIP: 00547W208
Event date: 2017-04-21
Legacy cover-page extraction is best effort and may not include every reporting person.
- Filing-level shares
- 1,500,000
- Percent of class
- 5.5700%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001019056-17-000376
- Form type
- SC 13G
- Filer
- DMK PHARMACEUTICALS Corp
- CIK
- CIK 887247
- Filed
- Apr 24, 2017
- Reporting period
- Apr 21, 2017
- Description
- Schedule 13G beneficial ownership